Jasper Therapeutics
Enabling safer conditioning agents to allow for expanded use of curative therapy with stem cell transplants and gene therapies.
Launch date
Employees
Market cap
€292m
Enterprise valuation
€197m (Public information from Sep 2024)
Share price
$23.91 JSPR
Redwood City California (HQ & founding location)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | - | - | - | - | - | 4.4m | 1.4m |
% growth | - | - | - | - | - | - | (68 %) |
EBITDA | (9.8m) | (43.1m) | (64.1m) | (67.2m) | - | - | - |
Profit | (31.7m) | (30.6m) | (37.7m) | (64.5m) | (61.6m) | (76.5m) | (99.5m) |
% profit margin | - | - | - | - | - | (1739 %) | (7069 %) |
EV / revenue | - | - | - | - | - | 42.5x | 234.0x |
EV / EBITDA | -12.8x | -7.0x | 0.3x | -1.3x | - | - | - |
R&D budget | 15.9m | 25.4m | 34.6m | 51.8m | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Series A | ||
$100m Valuation: $490m -50.0x EV/LTM EBITDA | SPAC IPO | ||
$100m Valuation: $490m -50.0x EV/LTM EBITDA | SPAC Private Placement | ||
* | N/A | $90.0m | Post IPO Equity |
* | $50.0m | Post IPO Equity | |
Total Funding | €90.9m |
Related Content
Recent News about Jasper Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.